ACA
ADPT icon

Atlas Capital Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Atlas Capital Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,000
Closed -$140K – 910
2021
Q4 		$140K Hold
5,000
– – 0.02% 408
2021
Q3 		$170K Hold
5,000
– – 0.03% 370
2021
Q2 		$204K Buy
+5,000
New +$194K 0.03% 355

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Atlas Capital Advisors's ADPT Position: Q1 2022 in Review

Atlas Capital Advisors sold out of Adaptive Biotechnologies (ADPT) in Q1 2022, closing a stake of 5,000 shares — an estimated $140K sold.

Atlas Capital Advisors first reported a position in ADPT in Q2 2021 and held it in 3 quarters. The position peaked at $204K in Q2 2021. 221 funds tracked by Wall St. Rank hold ADPT as of Q1 2022.

  • Atlas Capital Advisors reported no remaining Adaptive Biotechnologies position as of Q1 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 5,000 Adaptive Biotechnologies shares in Q1 2022, an estimated $140K.
  • Atlas Capital Advisors first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 3 quarters.
  • Atlas Capital Advisors's Adaptive Biotechnologies position peaked at $204K in Q2 2021.
  • 221 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2022.

Based on Atlas Capital Advisors's 13F filing for Q1 2022, filed 11 May 2022.